P1128: EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY
Elise R. A. Pennings(Amsterdam Neuroscience), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Anne M. Spanjaart(Amsterdam University Medical Centers), Eduardus F. M. Posthuma(Leiden University Medical Center), Pim Mutsaers(Erasmus MC Cancer Institute), Marjolein van der Poel(Maastricht University), Marie José Kersten(Hovon), Carin A. Uyl‐de Groot(Erasmus University Rotterdam), Tom van Meerten(University Medical Center Groningen), Otto Visser(Netherlands Comprehensive Cancer Organisation), Müjde Durmaz(Netherlands Comprehensive Cancer Organisation), Maria T. Kuipers(Amsterdam University Medical Centers), Joost S.P. Vermaat(Leiden University), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Frederick W. Thielen(University Medical Center Freiburg), Suzanne van Dorp(University Medical Center Utrecht), Margot Jak, Djamila E. Issa(Jeroen Bosch Ziekenhuis), Martine E.D. Chamuleau(Hovon)
Cited by 0
Related Papers
Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs
|Cancer Treatment Reviews|2016|616
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523
Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
|The Lancet Oncology|2017|510
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
|Seminars in Nuclear Medicine|2002|433